Live feed07:00:00·29dPRReleaseBeam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal DevelopmentBEAM· Beam Therapeutics Inc.Health CareOriginal source
